PTGS2 and non-small cell lung carcinoma: In advanced non-small cell lung cancer (NSCLC) patients with COX-2 expression undergoing chemotherapy, who received celecoxib had better survival than that in non-users, according to a randomized clinical trial (Edelman et al., 2008).